Met Life Investment Management, LLC Janux Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $16.5 Billion
- Q2 2025
A detailed history of Met Life Investment Management, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 23,876 shares of JANX stock, worth $579,470. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,876
Previous 18,663
27.93%
Holding current value
$579,470
Previous $503,000
9.54%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding JANX
# of Institutions
189Shares Held
57.5MCall Options Held
641KPut Options Held
171K-
Ra Capital Management, L.P. Boston, MA11.2MShares$272 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$112 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$88.7 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$80.8 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$56.9 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.01B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...